OBJECTIVE To evaluate the contemporary prevalence of urinary tract cancer (bladder cancer, upper tract urothelial cancer (UTUC) and renal cancer) in patients referred to secondary care with haematuria, adjusted for established patient risk markers and geographical variation. PATIENTS AND METHODS This was an international multicentre prospective observational study. We included patients aged 16 and over, referred to secondary care with suspected urinary tract cancer. Patients with a known or previous urological malignancy were excluded. We estimated the prevalence of bladder cancer, UTUC, renal cancer and prostate cancer; stratified by age, type of haematuria, sex and smoking. We used a multivariable mixed effects logistic regressio...
ABSTRACT Objective To evaluate the contemporary prevalence of urinary tract cancer (bladder cancer, ...
38siTo evaluate the contemporary prevalence of urinary tract cancer (bladder cancer, upper tract uro...
BACKGROUND: Patient factors associated with urinary tract cancer can be used to risk stratify patien...
OBJECTIVE To evaluate the contemporary prevalence of urinary tract cancer (bladder cancer, upper ...
Objective: To evaluate the contemporary prevalence of urinary tract cancer (bladder cancer, upper tr...
OBJECTIVE: To evaluate the contemporary prevalence of urinary tract cancer (bladder cancer, upper tr...
Objective: To evaluate the contemporary prevalence of urinary tract cancer (bladder cancer, upper tr...
Objective: To evaluate the contemporary prevalence of urinary tract cancer (bladder cancer, upper tr...
Objective: To evaluate the contemporary prevalence of urinary tract cancer (bladder cancer, upper tr...
OBJECTIVE: To evaluate the contemporary prevalence of urinary tract cancer (bladder cancer, upper tr...
Funder: Action Bladder Cancer UKFunder: Rosetrees Trust; Id: http://dx.doi.org/10.13039/501100000833...
Objective To evaluate the contemporary prevalence of urinary tract cancer (bladder cancer, upper tra...
Objective To evaluate the contemporary prevalence of urinary tract cancer (bladder cancer, upper tra...
Objective To evaluate the contemporary prevalence of urinary tract cancer (bladder cancer, upper tra...
Objective To evaluate the contemporary prevalence of urinary tract cancer (bladder cancer, upper tra...
ABSTRACT Objective To evaluate the contemporary prevalence of urinary tract cancer (bladder cancer, ...
38siTo evaluate the contemporary prevalence of urinary tract cancer (bladder cancer, upper tract uro...
BACKGROUND: Patient factors associated with urinary tract cancer can be used to risk stratify patien...
OBJECTIVE To evaluate the contemporary prevalence of urinary tract cancer (bladder cancer, upper ...
Objective: To evaluate the contemporary prevalence of urinary tract cancer (bladder cancer, upper tr...
OBJECTIVE: To evaluate the contemporary prevalence of urinary tract cancer (bladder cancer, upper tr...
Objective: To evaluate the contemporary prevalence of urinary tract cancer (bladder cancer, upper tr...
Objective: To evaluate the contemporary prevalence of urinary tract cancer (bladder cancer, upper tr...
Objective: To evaluate the contemporary prevalence of urinary tract cancer (bladder cancer, upper tr...
OBJECTIVE: To evaluate the contemporary prevalence of urinary tract cancer (bladder cancer, upper tr...
Funder: Action Bladder Cancer UKFunder: Rosetrees Trust; Id: http://dx.doi.org/10.13039/501100000833...
Objective To evaluate the contemporary prevalence of urinary tract cancer (bladder cancer, upper tra...
Objective To evaluate the contemporary prevalence of urinary tract cancer (bladder cancer, upper tra...
Objective To evaluate the contemporary prevalence of urinary tract cancer (bladder cancer, upper tra...
Objective To evaluate the contemporary prevalence of urinary tract cancer (bladder cancer, upper tra...
ABSTRACT Objective To evaluate the contemporary prevalence of urinary tract cancer (bladder cancer, ...
38siTo evaluate the contemporary prevalence of urinary tract cancer (bladder cancer, upper tract uro...
BACKGROUND: Patient factors associated with urinary tract cancer can be used to risk stratify patien...